Vol 55, No 1 (2021)
Letter to the Editors
Published online: 2021-01-29
Lacosamide and myoclonic seizures: what is the risk of aggravation?
1
, 2, 1
, 2, 1
Abstract
Not available
Keywords: lacosamidemyoclonic seizuresaggravationexacerbation
References
- Vossler DG, Knake S, O'Brien TJ, et al. SP0982 trial investigators. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2020; 91(10): 1067–1075.
- Chaves J, Sander JW. Seizure aggravation in idiopathic generalized epilepsies. Epilepsia. 2005; 46 Suppl 9: 133–139.
- Wężyk K, Słowik A, Bosak M. Predictors of remission in patients with epilepsy. Neurol Neurochir Pol. 2020; 54(5): 434–439.
- Swaminathan A, Kapoor S. A case report of exacerbation of myoclonus in idiopathic generalized epilepsy from use of lacosamide. Neurology. 2015; 84 (14 Suppl.) Abstracts: AAN 67th Annual Meeting.
- Birnbaum D, Koubeissi M. Unmasking of myoclonus by lacosamide in generalized epilepsy. Epilepsy Behav Case Rep. 2017; 7: 28–30.
- Belcastro V, Arnaboldi M, Taborelli A, et al. Induction of epileptic negative myoclonus by addition of lacosamide to carbamazepine. Epilepsy Behav. 2011; 20(3): 589–590.
- Abarrategui B, García-García ME, Toledano R, et al. Lacosamide for refractory generalized tonic-clonic seizures of non-focal origin in clinical practice: A clinical and VEEG study. Epilepsy Behav Case Rep. 2017; 8: 63–65.
- Wechsler RT, Yates SL, Messenheimer J, et al. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension. Epilepsy Res. 2017; 130: 13–20.
